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Abstract
The Karyopherin superfamily comprises nuclear transport proteins, involved in the shuttling of certain cargo proteins into
and out of the nucleus. Karyopherin b1 (Kpnb1) and Karyopherin a2 (Kpna2) are importin proteins, which work in concert to
transport their cargo into the nucleus. We previously identified increased expression of Kpnb1 and Kpna2 in cervical
tumours compared to normal epithelium and in transformed cells compared to their normal counterparts. This study
therefore aimed to identify the transcription regulatory mechanisms associated with high Kpnb1 and Kpna2 levels in cancer
cells. Kpnb1 (22013 to +100) and Kpna2 (21900 to +69) promoter fragments were separately cloned into the reporter
vector, pGL3-basic, and luciferase assays revealed both as significantly more active in cancer and transformed cells
compared to normal. A series of deletion constructs identified the 2637 to 2271 Kpnb1 and 2180 to 224 Kpna2 promoter
regions as responsible for the differential promoter activity, and a number of highly conserved E2F binding sites were
identified within these regions. Mutation analysis confirmed the requirement of E2F sites for promoter activity, and ChIP
analysis confirmed E2F2/Dp1 binding to the Kpnb1 and Kpna2 promoters in vivo. Dp1 inhibition resulted in decreased levels
of the respective proteins, confirming the role of E2F in the overexpression of Kpnb1 and Kpna2 proteins in cancer. E2F
activity is known to be deregulated in cervical cancer cells due to the inhibition of its repressor, Rb, by HPV E7. The
inhibition of E7 using siRNA resulted in decreased Kpnb1 and Kpna2 promoter activities, as did the overexpression of Rb. In
conclusion, this study is a first to show that elevated Kpnb1 and Kpna2 expression in cancer cells correlates with altered
transcriptional regulation associated with deregulated E2F/Rb activities
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Introduction
Karyopherin proteins are soluble nuclear transport receptors
that function in transporting cargo proteins and certain RNAs into
and out of the cell nucleus, via the nuclear pore complex (NPC)
[1]. Karyopherins may act as importins of exportins, depending of
their direction of transport. Karyopherin beta 1 (Kpnb1, also
known as Importin b or p97) is an importin protein that plays a
key role in the nuclear import process. Nuclear import via Kpnb1
can occur either by Kpnb1 acting as an autonomous nuclear
transport receptor, or through its association with an adaptor
protein, like Karyopherin alpha (Kpna, also known as Importin a),
in which case the import process is known as classical nuclear
import [2]. In the classical nuclear import pathway, the nuclear
localisation sequence (NLS) present in the cargo is recognised and
bound by the adaptor protein, Kpna, which then forms a trimer
complex with Kpnb1. The cargo:Kpna:Kpnb1 complex is
transported across the nuclear pore complex into the nucleus,
where upon it is dissociated by the binding of RanGTP. There are
six Kpna isoforms (Kpna1-6), which have been determined to
have preferential binding to specific substrates [3]. The function-
ing of all six isoforms thus broadens the substrate range carried
across the NPC.
We have recently shown that the expression of Kpnb1 and the
Kpna protein, Kpna2, is elevated in cervical cancer and
transformed cells at both the mRNA and protein levels [4]. We
found too that inhibition of Kpnb1 expression in cervical cancer
cells leads to cell death via apoptosis, suggesting that cervical
cancer cells become functionally dependent on Kpnb1 overex-
pression, highlighting the importance of Kpnb1 upregulation in
maintaining cancer biology. In our study Kpna2 inhibition had no
effect on cervical cancer cell viability [4]; it is possible that its
inhibition resulted in functional compensation by other Kpna
family members. Noetzel et al. [5] showed that breast cancer cells
underwent apoptotic cell death when Kpna2 was inhibited [5],
suggesting that in some cell lines it might be functionally
redundant, while in others it is functionally relevant. In addition,
many recent studies have identified high Kpna2 in tumour tissue,
suggesting that the upregulation of Kpna2 associates with cancer
development. Such cancers include melanoma [6], breast cancer
[7;8], oesophageal cancer [9], ovarian cancer [10], non-small cell
lung cancer [11], prostate cancer [12], bladder cancer [13] and
liver cancer [14]. Interestingly, Wang et al. [11] showed that
Kpna2 is secreted into the serum, suggesting it has potential
clinical usefulness as a cancer biomarker. In addition, several
studies have reported that high Kpna2 expression associates with
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poor patient survival [6–10;12;13], suggesting a potential prog-
nostic role for Kpna2.
While the overexpression of Kpnb1 and Kpna2 in cancer cells
appear to be significant events, little is known regarding their
transcriptional regulation and the factors that control their
expression and lead to their upregulation in cancer cells. In this
study, therefore, we cloned and analysed the Kpnb1 and Kpna2
promoters, and identified an important role for the transcription
factor, E2F, in the induction of Kpnb1 and Kpna2 expression in
cancer cells.
Results
Increased Kpnb1 and Kpna2 protein expression in
transformed and cancer cells correlates with increased
promoter activity
Based on our previous findings showing elevated Kpnb1 and
Kpna2 expression in cervical cancer cells and transformed cells
compared to normal, we investigated Kpnb1 and Kpna2 protein
expression in a representative normal, transformed and cervical
cancer cell line. These included the normal fibroblast cell line,
WI38, the SV40-transformed fibroblast cell line, SVWI38, and the
cervical cancer cell line, CaSki. Western Blot analysis revealed
elevated Kpnb1 and Kpna2 expression in the transformed and
cancer cells, compared to the normal WI38 cells (Fig. 1A). To
determine the transcriptional regulatory mechanisms that associ-
ate with elevated Kpnb1 and Kpna2 expression in cancer and
transformed cells, an approximate 2 Kb region upstream of the
transcription start site of the Kpnb1 and Kpna2 genes, together
with approximately 100 bp of their 59 untranslated regions
(downstream from the transcription start site), were separately
cloned into pGL3-Basic for promoter analysis. The 22013 to
+100 Kpnb1 and 21990 to +69 Kpna2 promoter constructs both
showed significantly higher activity in the transformed and cancer
cells compared to the normal WI38 cells (Fig. 1B and C).
Differential Kpnb1 and Kpna2 promoter activities in
normal, transformed and cancer cells derive from the
2637 to 2271 and 2180 to 224 regions of the Kpnb1
and Kpna2 promoters, respectively
In order to determine the regions responsible for the differential
activity of Kpnb1 and Kpna2 promoters in normal and
transformed/cancer cells, a series of deletion constructs were
generated and assayed for activity in WI38, SVWI38 and CaSki
cells. All deletion constructs of the Kpnb1 promoter displayed
significantly more activity in SVWI38 cells compared to WI38
cells (Fig. 2A). Notably in SVWI38 cells sequential deletion of the
22013 to 2637 region did not alter promoter activity, however,
deletion of the 2637 to 2271 region significantly diminished
Kpnb1 promoter activity (by approximately five-fold) (Fig. 2A). In
WI38 cells, deletion of this region had little effect on promoter
activity. In CaSki cells similar observations were made to those in
SVWI38 cells, where deletion of the region from 2637 to 2271
significantly altered Kpnb1 promoter activity (Fig. 2B). These
results suggest that important functional elements, necessary for
high Kpnb1 promoter activity in transformed and cervical cancer
cells, are likely to reside in the 2637 to 2271 region of the Kpnb1
promoter. With regards to Kpna2, deletion of the region from
1900 to 2180 had little effect on Kpna2 promoter activity in any
of the cell lines (Fig. 2C, D), suggesting that the region upstream of
2180 in the Kpna2 promoter does not confer transcriptional
activity. However, deletion of the region from 2180 to 224
resulted in significantly diminished promoter activity, almost to the
level of the empty vector, with the decrease in activity being more
pronounced in SVWI38 and CaSki cells, compared to WI38
(Fig. 2C, D). This suggests that important functional elements
necessary for high basal Kpna2 promoter activity in transformed
and cervical cancer cells reside in the 2180 to 224 region of the
promoter.
The Kpnb1 and Kpna2 promoters contain functional E2F
sites
A bioinformatic analysis of the regions 2637 to 2271 of the
Kpnb1 promoter and 2180 to 224 of the Kpna2 promoter (using
MatInspector and Conreal software programmes) identified a
number of putative binding sites for E2F. Deregulated E2F activity
is known to play a key role in cancer development; hence the
functionality of these putative E2F sites was investigated. Five
putative E2F binding sites were identified in the Kpnb1 (2637 to
2271) promoter region, and using site-directed mutagenesis (and
mutating at least three bases within the consensus binding sites),
mutant constructs were generated. Three E2F sites were found to
be functional, as their mutation resulted in significantly decreased
Kpnb1 promoter activity (Fig. 3A). This included the putative sites
labelled as E2F(a), E2F(b) and E2F(c). Interestingly, mutation of
these three sites simultaneously did not confer any further decrease
in promoter activity, compared to mutation of the E2F sites
individually, suggesting that they may work in concert to regulate
Kpnb1 gene expression (Fig. 3A). Of note, too, was the finding
that mutation of the E2F sites resulted in promoter activity
comparable to that of the 2271 to +100 construct, suggesting that
it is the E2F sites that are responsible for the increase in promoter
activity in the region from 2271 to 2637. Mutation of the three
E2F sites in the Kpnb1 promoter had a more pronounced effect
on promoter activity in SVWI38 and CaSki cells compared to that
in WI38 cells. These findings suggest that there is increased
reliance on the E2F sites in transformed and cancer cells,
compared to normal (Fig. 3B).
Bioinformatic analysis of the Kpna2 promoter, on the other
hand, revealed the presence of only one putative E2F site in the
2180 to 224 region. Interestingly, unlike the E2F sites in the
Kpnb1 promoter, mutation of this single E2F site completely
abolished Kpna2 promoter activity (Fig. 3C). Mutation of the E2F
site in SVWI38 and CaSki cells resulted in 84- and 57-fold
repression of promoter activity, respectively, while its mutation in
WI38 cells resulted in only 4-fold repression of the promoter
(Fig. 3D).
Together, these results suggest that the Kpnb1 promoter
contains E2F sites that act to enhance promoter activity, while
the Kpna2 promoter contains an E2F site that is involved in basal
promoter activation. In addition, E2F activation of both promoters
is more pronounced in transformed and cancer cells, compared to
normal.
E2F/Dp1 heterodimers bind and activate the Kpnb1 and
Kpna2 promoters in vivo
E2F functions as a heterodimeric transcription factor composed
of two subunits: an E2F family member and a Dp family member.
Although there are multiple E2F family members that are thought
to bind the same consensus sequence (59-TTTSSCGS-39; S refers
to C or G), E2F1, E2F2 and E2F3 have been shown to contain
strong oncogenic capacity [15], hence binding of E2F to the
Kpnb1 and Kpna2 promoters was investigated using an antibody
against E2F2 that cross-reacts with E2F1, E2F2 and E2F3. The
Dp protein family comprises proteins Dp1-3, with Dp1 having
been previously linked to cancer. To assess E2F2/Dp1 binding in
E2F Regulates Kpnb1 and Kpna2 Overexpression
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vivo, ChIP assays were performed using chromatin prepared from
SVWI38 and CaSki cells. DNA was immunoprecipitated using a-
E2F2 or a-Dp1 antibodies and used in a PCR with primers
spanning the E2F sites in the Kpnb1 and Kpna2 promoters
(Fig. 4A, B). Positive amplification in both SVWI38 and CaSki cell
lines confirmed an association between E2F2/Dp1 and the E2F
sites in both the Kpnb1 and Kpna2 promoters (Fig. 4A, B).
Further, to determine whether the binding of E2F/Dp1 to the
Kpnb1 and Kpna2 promoters was responsible for the elevated
levels of both Kpnb1 and Kpna2 proteins in vivo, E2F activity was
inhibited by silencing the expression of Dp1, without which E2F
can no longer function. Kpnb1 and Kpna2 protein levels were
measured by Western Blot analysis after Dp1 knock-down using
siRNA, and were found to decrease after Dp1 inhibition (Fig. 4C).
Kpnb1 and Kpna2 promoter activities were similarly repressed
upon Dp1 inhibition (Fig. 4D, E).
HPV E7 regulates Kpnb1 and Kpna2 promoter activities
in cervical cancer cells via the repression of Rb
In cervical cancer cells the HPV E7 protein is known to bind the
retinoblastoma (Rb) protein, leading to its phosphorylation and
ultimately degradation. It is for this reason that E2F target genes
are often overexpressed in cervical cancer, as E2F is no longer
repressed by Rb and is thus free to activate its target genes. Hence,
we hypothesised that the inhibition of HPV E7 in cervical cancer
cells would lead to restored Rb function, causing reduced E2F
activity, and thus diminished Kpnb1 and Kpna2 promoter
activities. To test this hypothesis, CaSki cells were transfected
Figure 1. Kpnb1 and Kpna2 protein levels in normal, transformed and cancer cells correlate with respective promoter activities.
A. Western Blot analysis of Kpnb1 and Kpna2 protein levels in normal WI38, transformed SVWI38, and cervical cancer CaSki cells reveals increased
expression in the cancer and transformed cells. B, C. 22013 to +100 Kpnb1 promoter activity (B) and 21900 to +69 Kpna2 promoter activity (C) was
measured in cell lysates prepared from transfected WI38, SVWI38 and CaSki cells, and was observed to be significantly higher in the transformed and
cancer cells compared to the normal cells (*p,0.05). TK-Renilla-Luc was used as a control for transfection efficiency and luciferase activity is
expressed relative to Renilla luciferase. Results shown are the mean 6 SD of experiments performed in triplicate and repeated at least two times.
doi:10.1371/journal.pone.0027723.g001
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with HPV16 E7 siRNA (Fig. 5A), and after confirming the
restoration of Rb (indicated in Fig. 5B by a decrease in levels of
phosphorylated Rb and an associated increased in unphosphory-
lated Rb), Kpnb1 (2637 to +100) and Kpna2 (2180 to +69)
promoter activities were measured. Kpnb1 and Kpna2 promoter
activities were significantly reduced in E7 knock-down cells,
compared to control cells, albeit to different extents (Fig. 5C and
D). To confirm that the decreased Kpnb1 and Kpna2 promoter
activities were via the restoration of Rb function, Rb was
overexpressed in CaSki cervical cancer cells and Kpnb1 and
Kpna2 promoter activities measured. Results showed that Kpnb1
and Kpna2 promoter activities were both significantly reduced on
overexpression of Rb (Fig. 5E and F). Together, these findings
suggest that the high Kpnb1 and Kpna2 expression levels in
cervical cancer cells is due in part to E7-mediated inhibition of Rb,
and the consequent increased activation of the Kpnb1 and Kpna2
promoters by E2F.
Discussion
In this study we cloned and analysed the Kpnb1 and Kpna2
promoters with an aim to identify potential regulatory mechanisms
that could drive their high expression in cancer cells. This study is
novel in that it is the first to our knowledge that describes E2F as
an important transcriptional regulator of Kpnb1 and Kpna2
expression in cancer cells. E2F plays a role in a diverse range of
cellular processes and has been reported to regulate the expression
of genes involved in differentiation, development, proliferation and
apoptosis [16]. It was previously reported that E2F plays a role in
the regulation of the RanBP1 gene [17], a major partner of the
Ran GTPase and integral to the nuclear transport process, and
our study, describing E2F-regulation of Kpnb1 and Kpna2
nuclear importer proteins, further implicates E2F in the regulation
of genes involved in nuclear transport.
E2F activity is controlled by the Rb pathway, whereby under
normal circumstances Rb binding to E2F represses E2F activity,
until the G1/S phase of the cell cycle, whereupon Rb becomes
phosphorylated by cdk4/cyclin D complexes, and E2F is released
to activate its target genes. However, E2F activity is often
deregulated in cancer, as a result of the frequent disruption of
the Rb pathway [18–21]. Rb mutations have been observed in a
wide spectrum of tumours, including osteosarcomas, small cell
lung carcinomas, breast carcinomas, and others. Moreover, in
many cancers the p16INK4a cdk inhibitor is mutated, or its function
is loss. This leads to elevated cdk4/cyclin D activity, resulting in
increased Rb phosphorylation and thus E2F accumulation.
Finally, deregulated expression and/or amplification of cyclin D
and cdk4 genes have also been observed in many cancers. This
leads to an increased level of cdk4/cyclin D activity and thus
similarly deregulation of the E2F pathway [21]. In cervical cancer,
the inactivation of the E2F repressor, Rb, by HPV E7, results in
increased E2F activity. As a result of frequent disruption of the
pathway that regulates E2F function, E2F target genes are often
overexpressed in cancer cells due to enhanced E2F transactivation
[22].
We show that overexpresion of Kpnb1 and Kpna2 in cancer is due
to, in part, increased activation of their promoters by E2F. A murine
study by Ishida et al. [23] identified a potential role for E2F in the
regulation of Kpna2 gene expression during the cell cycle. Our study
extends this finding and shows a role for E2F in the regulation of
human Kpna2, via a specific E2F site located at position 234 to 227
of the Kpna2 promoter. This E2F site appears essential for both basal
and activated Kpna2 gene expression. In addition, we identified three
functional E2F sites in the Kpnb1 promoter that appear to act in
concert to regulate Kpnb1 expression. It has been reported that
multiple E2F sites can exist in the promoter region of a gene, and that
these sites often co-operate to regulate gene expression [24].
The finding that Kpnb1 and Kpna2 genes are regulated by E2F
suggests that they are regulated in a cell cycle-dependent manner. It
has previously been reported that the nuclear import of karyopherin
a/b-substrates is more efficient at certain stages of the cell cycle
[25], in agreement with our data showing E2F-regulation of Kpnb1
and Kpna2. Overall, our findings suggest that the deregulated
activity of E2F in cancer cells causes increased activation of the
Kpnb1 and Kpna2 promoters, leading to elevated levels of these
proteins, and ultimately impacting the cancer phenotype.
Materials and Methods
Cell culture
WI38 normal lung fibroblasts, SVWI38 transformed WI38
fibroblasts, and CaSki cervical cancer cells were obtained from the
American Type Culture Collection (ATCC) (Rockville, MD,
USA). Cells were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with penicillin (100 U/ml),
streptomycin (100 mg/ml) and 10% Fetal Bovine Serum (FBS)
(Gibco, Paisley, Scotland). All cells were cultured at 37uC in a
humidified atmosphere of 5% CO2.
Protein harvest and Western Blot analysis
Cells in culture were grown to 80% confluency and lysed on ice
in RIPA buffer (10 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1%
deoxycholate, 0.1% SDS, 1% Triton X-100, 1 X Complete
Protease Inhibitor Cocktail (Roche, Basel, Switzerland)). Western
Blot analyses were performed using the rabbit anti-Kpnb1 (H-300)
(sc-11367, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
goat anti-Kpna2 (C-20) (sc-6917), rabbit anti-Dp1 (K-20) (sc-610),
mouse anti-HPV16 E7 (ED17) (sc-6981), mouse anti-Rb (4H1)
(#9309, Cell Signaling), and rabbit anti-b-tubulin (H-235) (sc-
9104, Santa Cruz Biotechnology) antibodies.
PCR amplification of the Kpnb1 (22013 to +100)
promoter
Primers were designed that would amplify the region from 22013 to
+100 of the Kpnb1 gene (GenBank Accession Number: NC_000017):
Kpnb1F 59 AGGCTAGCCCAGCTACATCCAATTACCC 39 and
Kpnb1R 59 AGAAGCTTCTGGGGGCAGCTCAGA 39 (NheI site
is underlined and HindIII site is in bold), and 21992 to +69 of the
Kpna2 gene (GenBank Accession Number: NC_000017): Kpna2F
59 AGTTCCCGGGGCAAAAGAAACTCAACTTGGC 39 and
Figure 2. Activity of Kpnb1 and Kpna2 promoter deletion constructs in WI38, SVWI38 and CaSki cells. A. Luciferase reporter constructs
containing deleted fragments of the human Kpnb1 promoter were transiently transfected into WI38 and SVWI38 cells, respectively. Luciferase activity
was significantly higher in the SVWI38 cells compared to normal WI38 cells for all constructs tested. The 2637 to +100 Kpnb1 promoter fragment
contained significantly more promoter activity than the 2271 to +100 fragment in transformed cells (*p,0.05). B. Activity of Kpnb1 promoter
deletion constructs in CaSki cells. C. Luciferase reporter constructs containing deleted fragments of the human Kpna2 promoter were transiently
transfected into WI38 and SVWI38 cells, respectively. Deletion of the 2180 to 224 promoter region resulted in significantly diminished promoter
activity. D. Activity of Kpna2 promoter deletion constructs in CaSki cells.
doi:10.1371/journal.pone.0027723.g002
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Kpna2R 59 AGAAGCTTGGGAATCAGCGGCTGTAG 39 (SmaI
site is italicised and HindIII site is in bold). PCR was performed using
100 ng normal blood DNA as template, and the high fidelity Expand
Plus DNA Polymerase (Roche). 5% DMSO was included in the PCR
for Kpnb1 to improve specificity. Promoter PCR products were
subcloned into the vector pGEM-T Easy (Promega) and the Kpnb1
(22013 to +100) fragment excised with NheI and HindIII restriction
enzymes, and the Kpna2 (21992 to +69) fragment excised with SmaI
and HindIII restriction enzymes, for subcloning into the luciferase
reporter plasmid, pGL3 Basic vector (Promega). There were difficulties
with the SmaI digest, hence SacI was used instead, as a SacI site was
present at position 21900 of the Kpna2 promoter. Subcloning into
pGL3 Basic placed the Kpnb1 (22013 to +100) and Kpna2 (21990 to
+69) promoter fragments upstream of the promoter-less luciferase gene
for promoter activity analysis. Constructs were verified by sequencing
using the UCT Human Genetics Sequencing Unit.
Figure 3. Functional E2F sites in the Kpnb1 (2637 to 2271) and Kpna2 (2180 to 224) promoter regions contribute to high
promoter activity in transformed and cancer cells. A. Mutation of the five putative E2F sites in the Kpnb1 (2637 to +100) promoter was carried
out by site-directed mutagenesis. Mutation of the three distal E2F sites lead to a significant decrease in Kpnb1 (2637 to +100) promoter activity, as
indicated by luciferase assays. Mutation of the three functional E2F sites simultaneously did not lead to any further decrease in promoter activity. B.
Mutation of the three E2F sites in SVWI38 and CaSki cells had a more profound impact on Kpnb1 promoter activity compared to that in WI38 cells
(numbers indicate fold repression). C. Mutation of the single E2F site in the Kpna2 promoter completely abolished promoter activity. D. Mutation of
the E2F site in SVWI38 and CaSki cells had a more profound impact on Kpna2 promoter activity compared to that in WI38 cells. Experiments are
shown as the mean 6 SE of experiments in quadruplicate performed at least two times (* p,0.05).
doi:10.1371/journal.pone.0027723.g003
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Generation of Kpnb1 and Kpna2 promoter deletion
constructs
Promoter deletion constructs for Kpnb1 were generated using
either restriction sites common to both the cloned promoter
fragment and the pGL3-Basic multiple cloning site (KpnI for the
2637 to +100 construct; SacI for the 2271 to +100 construct), or
gene-specific forward primers (59 AGGCTAGCGCCGTCAG-
GAGAGCTTGA 39 for the 2861 to +100 construct; 59
AGGCTAGCAGCGCCTGGCCAGTTAG 39 for the 2108 to
+100 construct; NheI restriction site is underlined) and the Kpnb1
R primer. The 2180 to +69 deletion construct for Kpna2 was
generated using NruI and SacI restriction enzymes, which released
the 21900 to 2180 fragment, while the 224 to +69 deletion
construct was generated using SwaI and SacI restriction enzymes,
which released the 21900 to 224 fragment.
Luciferase assays
100 ng of each promoter construct was transfected into 30 000
CaSki cervical cancer cells/well of a 24-well plate, using 0.3 ml
Transfectin (Bio-Rad). To normalise for transfection efficiency the
cells were co-transfected with 10 ng of the pRL-TK plasmid (that
encodes Renilla luciferase). Total cell lysates were prepared from cells
Figure 4. E2F/DP1 binds and activates the Kpnb1 and Kpna2 promoters in vivo. A, B. Samples of sonicated chromatin were
immunoprecipitated with an a-E2F2 antibody, an a-DP1 antibody, or no antibody, as indicated. DNA isolated from immunoprecipitated material was
amplified by PCR using primers spanning the E2F sites present in the Kpnb1 (A) or Kpna2 (B) promoters. Amplified fragments were analysed by
electrophoresis on a 2% agarose gel. Experiments were performed in both SVWI38 and CaSki cell lines. C. Western Blot showing Kpnb1 and Kpna2
protein levels after Dp1 inhibition using siRNA. b-tubulin was used as a control for protein loading. D, E. Kpnb1 and Kpna2 promoter activities after
Dp1 inhibition. Results shown are the mean 6 SE of experiments in quadruplicate performed at least two times (* p,0.05).
doi:10.1371/journal.pone.0027723.g004
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24 hr post-transfection using 1 X Passive Lysis Buffer (Promega) and
firefly luciferase activity was assayed using the Dual Luciferase Kit
(Promega). Luminescence was monitored using the Glomax 96
microplate luminometer (Promega). Activity was normalised to the
Renilla luciferase activity from pRL-TK in the same extract.
Site-directed mutagenesis of putative E2F sites
Mutations in the E2F binding sites of the Kpnb1 promoter were
prepared by site-directed mutagenesis, using mutagenic primers:
E2Fa: F: 59 CGCTCAGGCCCGCtAgcACCTCGCGCAACAC
39; E2Fa: R: 59 GTGTTGCGCGAGGTgcTaGCGGGCCT-
GAGCG 39; E2Fb: F: 59 GAACCCAGCTCCGCCTCTTgC-
taGcGGCGTCCCATCGTGCCCC 39; E2Fb: R: 59 GGGGC-
ACGATGGGACGCCgCtaGcAAGAGGCGGAGCTGGGTTC
39; E2Fc: F: 59 GCTCCTAGGGTTGCtaGcCACCTC-
CCGCCTTCC 39; E2Fc: R: 59 GGAAGGCGGGAGGTGgC-
taGCAACCCTAGGAGC 39; E2Fd: F: 59 CGGGCACCTC-
CCGCCTgCtaGCGCCCCGACCCCGAAC 39; E2Fd: R: 59
GTTCGGGGTCGGGGCGCtaGcAGGCGGGAGGTGCCCG
39; E2Fe: F: 59 CTCCTCTCCTTAGTTCTCgCtaGCACCC-
TATCCTATCAAC 39; E2Fe: R: 59 GTTGATAGGA-
TAGGGTGCtaGcGAGAACTAAGGAGAGGAG 39 (mutated
bases are indicated in lowercase; NheI restriction site is
underlined). Mutation of the E2F binding site in the Kpna2
promoter was carried out using mutagenic primers: F 59
CAATCGGAATGCGGAGTCgCtaGcAAATTTAAATCGCG-
CCGGGC 39 and R 59 GCCCGGCGCGATTTAAATTTgC-
taGcGACTCCGCATTCCGATTG 39. PCR was performed
using the following conditions: 95uC for 30 seconds, followed by
18 cycles of 95uC for 30 seconds, 61uC for 1 minute, and 72uC for
Figure 5. HPV E7 inhibition and Rb overexpression affects the activity of the Kpnb1 and Kpna2 promoters. A, B. HPV16 E7 siRNA was
used to inhibit E7 expression in CaSki cells and Western blot analysis performed to analyse HPV E7 (A) and Rb (B) levels after HPV E7 knock-down.
C, D. Kpnb1 (C) and Kpna2 (D) promoter activities were measured after E7 siRNA transfection, and were found to be significantly inhibited after HPV
E7 inhibition. E, F. Rb was overexpressed in CaSki cells and Kpnb1 (E) and Kpna2 (F) promoter activities were found to be significantly inhibited.
Results shown are the mean 6 SE of experiments in quadruplicate performed at least two times (* p,0.05).
doi:10.1371/journal.pone.0027723.g005
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6 minutes, followed by a final extension step of 72uC for 20
minutes. Following PCR amplification, 10 U DpnI (Promega) was
added and digestion carried out at 37uC for 90 minutes, before
transformation into JM109 highly competent cells (Promega).
Restriction digestion analysis was used to identify clones carrying
the mutation.
Chromatin immunoprecipitation (ChIP) assay
Cells were grown to approximately 90% confluency and protein-
DNA complexes cross-linked with 1% formaldehyde for 10 minutes,
followed by the addition of 0.125 M Glycine, pH 2.5. Cells were
harvested, lysed in lysis buffer (1% SDS, 5 mM EDTA, 50 mM Tris-
Cl, pH 8.1, 1 X Complete Protease Inhibitor (Roche)), and sonicated
to lengths of between 400 and 1000 bp. Cell lysates were diluted in
dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris-Cl, pH 8.1, 1 X Complete Protease Inhibitor) and then
precleared with protein-A agarose beads (Merck, NJ, USA) for 2 hr.
Beads had been previously blocked in 100 mg/ml salmon sperm
DNA and 5% BSA. Chromatin was incubated with 2 mg antibody (a-
E2F 2 (C-20 X, sc-633 X, Santa Cruz Biotechnology); a-DP1 (K-20,
sc-610, Santa Cruz Biotechnology); or no antibody negative control)
at 4uC overnight. Protein-A agarose beads were added for a further
2 hr at 4uC, and immunocomplexes bound by the beads recovered
by centrifugation and washed twice sequentially in TSE I (0.1% SDS,
1% Triton X-100, 2 mM EDTA, 20 mM Tris-Cl, pH 8.1, 150 mM
NaCl), TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris-Cl, pH 8.1, 500 mM NaCl), Buffer III (0.25 M LiCl, 1% NP-
40, 1% Sodium Deoxycholate, 1 mM EDTA, 10 mM Tris-Cl,
pH 8.1) and TE, pH 7.4. Bound material was eluted using elution
buffer (1% SDS, 0.1 M NaHCO3) at room temperature for 10
minutes, and the input and eluted samples heated at 65uC overnight
to reverse the formaldehyde cross-links. DNA was purified and used
for real-time PCR, using primers designed to span the E2F binding
sites (Kpnb1 F: 59 GCCATTAAAGCAGCTTCCTG 39; Kpnb1 R:
59 CGGCAACCCTAGGAGC 39; Kpna2 F: 59 CCCCAAGCCC-
TATGACTC 39; Kpna2 R: 59 GGGAATCAGCGGCTGTAG 39).
These primers amplified a 199 bp and 204 bp product, respectively.
siRNA transfection
For the effect of Dp1 siRNA on Kpnb1 and Kpna2 protein levels,
120 000 CaSki cells were plated in 35 mm dishes and transfected
with 20 nM control siRNA-A (sc-37007, Santa Cruz Biotechnology)
or Dp1 siRNA (sc-37813) for 72 hours, after which protein was
harvested using RIPA buffer and Western Blot analysis performed.
For the effect of HPV E7 siRNA on Kpnb1 and Kpna2 promoter
activities, cells were transfected with 20 nM HPV16 E7 siRNA. E7
siRNA was designed as described by Tang et al., 2006 [26]. RNA
oligos were synthesised by Ella Biotech GmBH (Germany) and
annealed in a reaction containing 30 ml each RNA oligo (50 mM)
and 15 ml annealing buffer (100 mM Potassium acetate, 20 mM
Hepes, pH 7.4, 2 mM Magnesium acetate) at 90uC for 1 minute,
followed by 37uC for 1 hour, to give a final siRNA concentration of
20 mM. 24 hours after siRNA transfection cells were trypsinised and
replated in 24-well plates, at 40 000 cells/well. 24 hours later, cells
were co-transfected with 50 ng Kpnb1 (2637/+100) or Kpna2
(2180/+69) promoter constructs and 5 ng pRL-TK plasmid.
Luciferase activity was measured 72 hours after siRNA transfection
and expressed relative to Renilla luciferase in the same extract.
Rb overexpression
To assay for the effect of Rb overexpression on Kpnb1 and
Kpna2 promoter activities, cells were co-transfected with 100 ng
pCMV or RcCMV/Rb (Addgene plasmid 1763, provided by Bob
Weinberg), 50 ng promoter construct and 5 ng Renilla, using
0.45 ul Transfectin per well. Cells were incubated for 48 hours
after transfection, and luciferase assays performed.
Statistical analysis
Experiments were performed in triplicate or quadruplicate and
are represented as the mean 6 standard error of the mean (SEM).
For group comparisons the Student’s t-test was used, where two-
tailed paired tests were used and a p-value of less that 0.05
considered statistically significant.
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